5 active sites I see being reported but I unfortunately was not able to listen personally.

The link he posts for a “comprehensive analysis” does not seem to work for me. Can you or anyone else verify?

Since there is not much here today on this board, I thought I would do a little whining.

In my taxable account, AMRN is my only non-dividend paying stock (after retiring purchased divvy stocks for income), and in my retirement accounts AMRN is among several spec stocks although I have been gradually shifting those accounts into divvy stocks since next year I have to start taking RMDs. Looking at the portfolio, on the whole the stocks have done quite well, even those other spec stocks. BUT AMRN is amazing, in that even crappy stocks bounce every 6 or 12 months, but here with Amarin we are just mired in quicksand. If by some fluke this damn thing could pop up to $4 or $5, my financial situation would be set. Just hard to understand how this can just sit, sit, sit, slide, sit, sit, slide..... ad infinitum. I suppose, like I have said before, the market looks at future prospects and it does not comprehend how income can come in sufficiently fast enough to stem the losses. We need some new developments but damn if I can see any on the horizon. Anyway sorry for the rant.

227 times average volume today on no news that I can find. Obviously someone thinks they know something. Maybe they know nothing. We are always last to know.

Thanks for posting Sleven. Really good information. Wondering if with their last sentence they were slightly covering their asses by saying all this could be invalid if dietary cholesterol is consumed with say fat. Well an egg has 1.5g of sat fat. Quite possibly (don’t have time to check now) all sources of cholesterol have some quantity sat fat?

Nuke, you bring up an interesting question. Not sure if this has something to do with Australia's reimbursement scheme. Is it possible the $32 is what the patient (consumer) has to pay but that the Australian govt actually pays Amarin (or whoever is distributing it there?) more than that?

Thanks Capt. Is this the new form that will require less caps per day? Bioequivalence worries me because isn’t that what GV had to show? A equivalent to B and B equivalent to C would mean A equivalent to C.

Nightmare would be if insurance cos and PBM would sub GV for it. But can I assume the new patent would take care of that?

Does anyone have an idea as to what regulatory hurdles there would be with respect to rolling out any of these enhanced absorption EPA forms?

Thanks for posting. That makes sense.

Thanks Kiwi. From what I can gather from the docs, some purchases were made on Sept. 30.

Probably a good purchase. If no sale of company you still would lose very little if any.

Doesn’t MAT9001 belong to Matinas Bio?

I have been saying or asking the same thing for some time. They have a product that ultimately they have to sell. Not sure they need to be listed to access stuff as some companies that want to be a going concern. Time to get revenues up and reimbursements in place and then sell to a BP.

I did that on two previous occasions thinking that the stock price was at a low point. Needless to say those didn’t work out very well for me, but to be fair, we only have 60 cents more to lose so you are probably right.

North, I wonder if it is possible that this discounted price on GoodRx has only been put into effect very recently and was not in effect 30 days ago.

Does that imply that Wainwright is assuming either CMS loses or the Kidney Act passes?

Thanks for posting. Good to know. Of course those with insurance would still pay less than that for GV.

You have to expand those results sections to see it.

Unfortunately I am not as confident. What I can’t understand is how someone who should know his way around the stock market could possible authorize or pursue a RS, if indeed that is what actually happens. A RS split is not negative only when a company has positive and growing earnings. Otherwise the loss per share gets magnified and the market drives the stock price back from whence it came prior to RS.

But I appreciate your post as it gives me a glimmer of hope that the nonsense of a RS is not undertaken.

I think price-wise we can (I believe successful AGs can still command a slightly higher price than Generics) but since the Generics have so many products and connections with the pharmacies, that I have always thought it would be tough slough.

It is the CVS Caremark decision that makes me wonder if an AG might make sense. Let me explain. CVS Caremark has stopped brand on the formulary (commercial) but although I could be wrong I believe they cover GV no matter the manufacturer. So they would automatically cover an AG. Willing yo stand corrected on this.

Many times I am obviously too dumb to think of or anticipate developments with this stock but if I had to come up with something I would say this.

Here in the US there would have to be some legal victories, or possibly the introduction of an AG. Could there be some deal or arrangement with a statin mfr to market a combo?

Outside of the US it seems more reimbursement approvals and an acceleration of scripts in ROW would be a welcome positive.

From the depths of despair the stock this morning is perking up. Hoping this is some positive surprise.

Agree with all your points except wrt China. In that aspect, I am from Missouri. I will make up my mind once I see the results. Knowing what China typically does stealing IP, has me leery, but I will reserve judgement until we see what happens there.

It is also possible that it is the DHA portion of fish oil that plays a more active role in factors affecting the brain.

As an investor in Amarin I have always thought that the CVD benefits of V was all that we needed to be very successful but management became a Business 101 glowing example of how to botch a golden egg.

I have to assume like you and JRoon that Raggy must have been referring to the buyback. Some of us think that it may have been prudent to abort that once they found out about the CVS Caremark commercial decision to drop V.

I may be naive, but to me it seems if the ultimate goal is to sell V that it would not be necessary to worry about where the stock is listed, hence no need for RS. At least in the short to medium term we shareholders would get creamed in a RS.

Yep, home safe and sound. Funny about Tang and Kezar. They stopped the trial for LN and now FdA issuing a clinical hold. Would love to know Tang’s thinking on this.

Maybe the market believes the press release that it was not because of any disagreement or shenanigans with Amarin but rather that he left for what he deems to be a better opportunity with the eye drug company he joined.

Well hopefully an overreaction. Sitting in SLC waiting for last leg to PDX.

Who is Richard C? This is the only guy I can find:

https://www.hetwebsite.net/het/profiles/cantillon.htm

Me either. IIRC, I may have first started posting on Investor Village ( I know I posted there when I was invested in Elan), but can’t remember when I started posting here. It seems many of the posters that I remember from pre R-I days are either no longer here, or post very infrequently. And of course we remember the tragic event with BioBillionaire.

Patient………that’s me. Been here for more than 13 years (since before Marine approval).

No question that GIA is/was the most ridiculous idea for a small bio. Morons like myself know that so it is amazing that management wouldn’t. But ego gets tge best of many of them. In our case Thero - twice. Once in not selling the company ( yeah I know some will say there was no interest but that doesn’t wash as there is always some interest but it may have been chased away by greedy ideas about what the company was worth) and secondly piss-poor fiduciary function regarding the patent lawsuit - first in selecting the worst district to defend the lawsuit and then not settling the suit before the verdict. And that of course does not mention the horrendous job their legal team did.

Yep:

“However, factors such as patent challenges, generic competition, and market access can affect these projections.”

“ VASCEPA in China, its import and USE have significantly expanded.” (My emphasis on “use”.

So is Amarin or Edding getting any monies for this significantly expanded use?

Thanks Sleven. Would be interesting to know what they are doing with it.

No, opposite side of the state - 7 miles south of Daytona. Track of storm right now runs right through Orlando. Hoping it stays slow moving and our booked flight can get out Tues afternoon.

Thanks for the article. I had previously seen it a while back and it is a good explanation of both drugs. However I guess it still comes down to what the person’s insurance co wants to do.

Yep, docked in Ft Lauderdale yesterday morning, rented a car and drove a couple of hundred miles north to spend the next few days seeing friends, etc where we spent 45 years of lives. Due to fly out of Orlando Tuesday afternoon, but now worried the approaching hurricane may throw a monkey wrench in that.

Sounds like the National Guard has been doing yeoman work from as soon as it was possible:

https://www.nationalguard.mil/News/Article-View/Article/3919179/national-guard-rescues-hundreds-of-people-in-wake-of-hurricane/

Hats off to your son and you as well.